Home » GW Pharmaceuticals’ Epidiolex Shines in Phase 3
GW Pharmaceuticals’ Epidiolex Shines in Phase 3
GW Pharmaceuticals saw positive results in a Phase 3 study evaluating its epilepsy candidate Epidiolex for the treatment of Dravet syndrome.
Patients treated with Epidiolex experienced a “significant reduction” in seizure frequency versus the placebo.
GW has two ongoing Phase 3 trials evaluating Epidiolex in Lennox-Gastaut syndrome and second Phase 3 trial in Dravet syndrome.
Additionally, Epidiolex garnered fast track status from the FDA and orphan drug designation from the European Commission for Dravet syndrome.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May